Rating Change
Cantor Fitzgerald reiterated its Neutral rating on Bristol-Myers Squibb Company (NYSE:BMY) on October 08, 2026.
reiterateNYSE:BMY
Cantor Fitzgerald Reiterates Neutral Rating on Bristol-Myers Squibb Company (BMY)
Cantor Fitzgerald reiterated its Neutral rating on Bristol-Myers Squibb Company (NYSE:BMY) on October 08, 2026.
At publication ·
What changed
Bristol-Myers Squibb Company (NYSE:BMY) · reiterate
- Firm
- Cantor Fitzgerald
- Rating
- Neutral to Neutral
- Price at event
- $59.58
- Market capitalization
- $104.2B
At a glance
Key takeaways
- Cantor Fitzgerald maintained a Neutral rating on Bristol-Myers Squibb (BMY) on October 8, 2026, with the stock trading at $59.58 and a market cap of $104.2 billion.
- Among the 10 most recent analyst ratings, BMY has 4 Buy ratings, 5 Hold ratings, and 1 Sell rating, showing mixed sentiment across analysts.
- BMY stock has gained 9.8% over the past 52 weeks, though analyst opinions remain divided on the company's near-term prospects.
- Recent analyst activity includes downgrades from Morgan Stanley to Underweight and upgrades from Piper Sandler to Overweight, indicating changing market perspectives.
Market Context
Bristol-Myers Squibb Company operates in the Healthcare sector. The stock currently trades at $59.58 with a market capitalization of $104.2B. The stock has gained 9.8% over the past 52 weeks.
Analyst coverage from Cantor Fitzgerald provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Bristol-Myers Squibb Company.
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Recent Analyst Activity for Bristol-Myers Squibb Company
Among the 10 most recent ratings: 4 Buy, 5 Hold, 1 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Oct 08, 2026 | Cantor Fitzgerald | Neutral | N/A |
| Oct 07, 2026 | Morgan Stanley | Underweight | N/A |
| Oct 05, 2026 | Leerink Partners | Market Perform | N/A |
| Sep 16, 2026 | Piper Sandler | Overweight | N/A |
| Sep 10, 2026 | HSBC | Hold | N/A |
Related Tools: Analyst Ratings Dashboard | View BMY Stock Page
Frequently Asked Questions
What does the Neutral rating mean for BMY?
A rating of Neutral from Cantor Fitzgerald reflects the analyst's outlook on Bristol-Myers Squibb Company (NYSE:BMY). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Where can I find more analyst ratings?
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the BMY forecast page.
Loading related coverage…
